[Studies in 25 patients with progressive systemic scleroderma treated by long-term administration of griseofulvin].
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002986:Clinical Trials as Topic; D005069:Evaluation Studies as Topic; D005260:Female; D006118:Griseofulvin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008599:Menstruation Disturbances / Q000139:chemically induced; D008875:Middle Aged; D010146:Pain / Q000139:chemically induced; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors; D014717:Vertigo / Q000139:chemically induced
D007166:Immunosuppressive Agents; D006118:Griseofulvin
Osservazioni eseguite in 25 pazienti di sclerodermia sistemica progressiva curati mediante somministrazione a lungo termine di griseofulvina.